Current data and future perspectives on DNA methylation in ovarian cancer (Review) DOI Creative Commons
Mengyu Fu,

Fengying Deng,

Jie Chen

и другие.

International Journal of Oncology, Год журнала: 2024, Номер 64(6)

Опубликована: Май 8, 2024

Ovarian cancer (OC) represents the most prevalent malignancy of female reproductive system. Its distinguishing features include a high aggressiveness, substantial morbidity and mortality, lack apparent symptoms, which collectively pose significant challenges for early detection. Given that aberrant DNA methylation events leading to altered gene expression are characteristic numerous tumor types, there has been extensive research into epigenetic mechanisms, particularly methylation, in human cancers. In context OC, is often associated with regulation critical genes, such as BRCA1/2 Ras‑association domain family 1A. Methylation modifications within promoter regions these genes not only contribute pathogenesis but also induce medication resistance influence prognosis patients OC. As such, more in‑depth understanding underpinning carcinogenesis could potentially facilitate development effective therapeutic approaches this intricate disease. The present review focuses on classical suppressor oncogenes, signaling pathways microRNAs an aim elucidate progression advantages limitations employing diagnosis, treatment prevention OC discussed. On whole, literature indicates specific serve prognostic biomarker target personalized strategies. Further investigations field may yield efficacious diagnostic alternatives

Язык: Английский

Rapid Detection of Npy Methylation in Colorectal Cancer Using a Singlet Oxygen-Based Photoelectrochemical Ratiometric Bio-Platform DOI
Alexandr Stratulat, Alejandro Valverde, Laura Mariën

и другие.

Опубликована: Янв. 1, 2025

Язык: Английский

Процитировано

0

Single Methylation Sensitive Restriction Endonuclease-Based Cascade Exponential Amplification Assay for Visual Detection of DNA Methylation at Single-Molecule Level DOI

Parezhati Pataer,

Pengbo Zhang, Zhengping Li

и другие.

Analytical Chemistry, Год журнала: 2024, Номер 96(32), С. 13335 - 13343

Опубликована: Авг. 2, 2024

Function as a potential cancer biomarker, DNA methylation shows great significance in diagnosis, prognosis, and treatment monitoring. While the lack of an ultrasensitive, specific, accurate method at single-molecule level hinders analysis exceedingly low levels methylation. Herein, based on outstanding recognition digestion ability methylation-sensitive restriction endonuclease (MSRE), we established single MSRE-based cascade exponential amplification method, which requires only two ingeniously designed primers one site MSRE for detection Differentiated by digestion, cleaved unmethylated is too short to induce any reactions, while methylated remains intact trigger subsequent CRISPR/Cas12a system. By integrating 1 aM can be accurately detected, corresponds 6 molecules 10 μL system, indicating that our more sensitive than amplification-based methods with detect level. In addition, 0.1% effectively distinguished from large amounts DNA. Our further introduced exploit expression difference among normal cells cells. Moreover, visual also realized full hybridization between products crRNA CRISPR/Cas12a. Therefore, proposed has promising robust bisulfite-free level, importance early diagnosis cancer.

Язык: Английский

Процитировано

1

An introduction to personalized medicine DOI
Joshua A. Bornhorst

Therapeutic Drug Monitoring, Год журнала: 2024, Номер unknown, С. 331 - 354

Опубликована: Янв. 1, 2024

Pharmacogenetic testing (PGx), a necessary component of personalized medicine, is powerful tool to assist in prescribing safe and efficacious medications individual patients. PGx utilizes the information provided by an individual's unique genetic makeup potentially predict both pharmacokinetic profiles pharmacodynamic response for increasing number xenobiotics. This chapter will provide broad overview pharmacogenetic approaches. More recent pharmacogenomics approaches discoveries, such as genome-wide association studies pathway analyses candidate genes, also be discussed. comment on challenges advantages integrating part medicine philosophy, which advocates rational, individualized pharmacotherapy.

Язык: Английский

Процитировано

0

Current data and future perspectives on DNA methylation in ovarian cancer (Review) DOI Creative Commons
Mengyu Fu,

Fengying Deng,

Jie Chen

и другие.

International Journal of Oncology, Год журнала: 2024, Номер 64(6)

Опубликована: Май 8, 2024

Ovarian cancer (OC) represents the most prevalent malignancy of female reproductive system. Its distinguishing features include a high aggressiveness, substantial morbidity and mortality, lack apparent symptoms, which collectively pose significant challenges for early detection. Given that aberrant DNA methylation events leading to altered gene expression are characteristic numerous tumor types, there has been extensive research into epigenetic mechanisms, particularly methylation, in human cancers. In context OC, is often associated with regulation critical genes, such as BRCA1/2 Ras‑association domain family 1A. Methylation modifications within promoter regions these genes not only contribute pathogenesis but also induce medication resistance influence prognosis patients OC. As such, more in‑depth understanding underpinning carcinogenesis could potentially facilitate development effective therapeutic approaches this intricate disease. The present review focuses on classical suppressor oncogenes, signaling pathways microRNAs an aim elucidate progression advantages limitations employing diagnosis, treatment prevention OC discussed. On whole, literature indicates specific serve prognostic biomarker target personalized strategies. Further investigations field may yield efficacious diagnostic alternatives

Язык: Английский

Процитировано

0